Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...

Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...

Q1 2025 delivered first positive adjusted EBITDA result since 2021 and guided to a break-even adjusted EBITDA result for ...